Skip to main content
Premium Trial:

Request an Annual Quote

GenomeDx, Mayo Expand Research Agreement

NEW YORK (GenomeWeb) – GenomeDx announced today an expansion of its research agreement with the Mayo Clinic to start a validation study for the expanded use of GenomeDx's Decipher Prostate Cancer Classifier.

GenomeDx will have continued access to clinical data from Mayo's cohort of prostate cancer samples, enabling the San Diego-based firm to conduct longer-term follow-up and evaluation of biomarkers. The partners began collaborating in 2009, and in 2013 they expanded their deal to include an exclusive license to certain co-developed and Mayo-developed intellectual property.

The Decipher test analyzes whole genomes to profile RNA expression signatures. It measures the aggressiveness of prostate cancer in patients who have had a prostatectomy and classifies a patient's risk of disease progression, metastasis, and prostate-related death after a prostatectomy.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.